Interpace Diagnostics ROE 2006-2018 | IDXG

Current and historical return on equity (ROE) values for Interpace Diagnostics (IDXG) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Interpace Diagnostics ROE for the three months ending September 30, 2018 was -33.67%.
Interpace Diagnostics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $-0.01B $0.04B -33.55%
2018-06-30 $-0.01B $0.04B -33.55%
2018-03-31 $-0.02B $0.04B -44.74%
2017-12-31 $-0.01B $0.04B -35.04%
2017-09-30 $-0.00B $0.04B -3.85%
2017-06-30 $-0.01B $0.04B -29.85%
2017-03-31 $-0.00B $0.03B -10.81%
2016-12-31 $-0.01B $0.01B -160.00%
2016-09-30 $-0.01B $-0.00B -153.85%
2016-06-30 $-0.01B $0.01B -96.97%
2016-03-31 $-0.01B $0.01B -140.54%
2015-12-31 $-0.01B $0.01B -104.35%
2015-09-30 $-0.02B $0.01B -173.58%
2015-06-30 $-0.02B $0.01B -122.22%
2015-03-31 $-0.02B $0.02B -79.12%
2014-12-31 $-0.02B $0.02B -60.95%
2014-09-30 $-0.01B $0.03B -44.44%
2014-06-30 $-0.01B $0.03B -34.38%
2014-03-31 $-0.01B $0.03B -26.28%
2013-12-31 $-0.01B $0.03B -13.89%
2013-09-30 $-0.03B $0.04B -67.57%
2013-06-30 $-0.02B $0.04B -56.14%
2013-03-31 $-0.02B $0.04B -47.67%
2012-12-31 $-0.03B $0.04B -46.51%
2012-09-30 $-0.01B $0.06B -18.41%
2012-06-30 $-0.01B $0.06B -16.00%
2012-03-31 $-0.01B $0.06B -16.99%
2011-12-31 $-0.01B $0.06B -17.84%
2011-09-30 $-0.01B $0.07B -7.17%
2011-06-30 $-0.01B $0.07B -9.96%
2011-03-31 $-0.01B $0.07B -9.82%
2010-12-31 $-0.01B $0.07B -11.07%
2010-09-30 $-0.02B $0.07B -31.29%
2010-06-30 $-0.03B $0.07B -33.02%
2010-03-31 $-0.03B $0.07B -35.40%
2009-12-31 $-0.03B $0.08B -37.06%
2009-09-30 $-0.03B $0.09B -33.08%
2009-06-30 $-0.04B $0.10B -34.42%
2009-03-31 $-0.04B $0.10B -33.55%
2008-12-31 $-0.03B $0.11B -27.09%
2008-09-30 $-0.02B $0.12B -14.21%
2008-06-30 $-0.01B $0.13B -10.14%
2008-03-31 $-0.01B $0.14B -6.37%
2007-12-31 $-0.01B $0.14B -6.97%
2007-09-30 $-0.00B $0.14B -2.06%
2007-06-30 $0.00B $0.15B 0.68%
2007-03-31 $0.00B $0.15B 2.74%
2006-12-31 $0.01B $0.15B 8.30%
2006-09-30 $-0.01B $0.14B -9.20%
2006-06-30 $-0.02B $0.14B -11.81%
2006-03-31 $-0.01B $0.14B -8.70%
2005-12-31 $-0.02B $0.14B -12.22%
Sector Industry Market Cap Revenue
Medical Medical Services $0.027B $0.016B
Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey.
Stock Name Country Market Cap PE Ratio
ICON (ICLR) Ireland $7.844B 24.58
PRA Health Sciences (PRAH) United States $7.421B 30.29
Charles River Laboratories (CRL) United States $6.793B 23.40
NovoCure (NVCR) Jersey $4.947B 0.00
Premier (PINC) United States $4.872B 16.51
Teladoc (TDOC) United States $4.868B 0.00
HealthEquity (HQY) United States $4.810B 94.02
AMN Healthcare Services Inc (AMN) United States $2.603B 16.88
BioTelemetry (BEAT) United States $2.584B 45.64
Medpace Holdings (MEDP) United States $2.505B 31.00
Intrexon (XON) United States $1.103B 0.00
CareDx (CDNA) United States $1.031B 0.00
Natera (NTRA) United States $1.023B 0.00
Healthways (TVTY) United States $0.861B 10.59
China Cord Blood (CO) China $0.808B 22.17
Apollo Medical Holdings (AMEH) United States $0.698B 0.00
Surgery Partners (SGRY) United States $0.665B 0.00
Civitas Solutions (CIVI) United States $0.643B 10.61
Establishment Labs Holdings (ESTA) $0.527B 0.00
Imprimis Pharmaceuticals (HROW) United States $0.143B 0.00
OpGen (OPGN) United States $0.012B 0.00
Cancer Genetics (CGIX) United States $0.007B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.002B 0.00